TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10383498
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg, clarithromycin 250 mg, and metronidazole 400 mg (OMC)
Study: 30590857
Drug: Reboxetine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (4 mg) plus hyoscine butylbromide (20 mg)
Study: 28002986
Drug: Copper supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper supplementation (1000 mg per day)
Study: 20942287
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at acupoints compound general anesthesia (group B)
Study: 20942287
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at non‐acupoints compound general anesthesia (group C)
Study: 18380632
Drug: Warfarin arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin arm of SPORTIF III
Study: 10917401
Drug: Fluvoxamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100 to 200 mg/day) combined with neuroleptics
Study: 8702053
Drug: Urodilatin (URO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urodilatin (URO) infusion (20 ng/kg bw/min)
Study: 8702053
Drug: Urodilatin (URO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urodilatin (URO) infusion
Study: 1687130
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg Salbutamol (after last dose)
Study: 26782254
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with primary tumor resection (PTR)
Study: 25007865
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate 100 μg once daily
Study: 25007865
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate 200 μg once daily
Study: 25007865
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate 100 μg and 200 μg once daily
Study: 21055090
Drug: Standardized dust
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized dust mite allergen specific immunotherapy (SIT)
Study: 10559514
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of LNMMA (8 and 16 micromol/min) followed by intracoronary administration of 250 mcg nitroglycerin
Study: 10559514
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of LNMMA
Study: 8565164
Drug: OPC-18790 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-18790 (5 micrograms.kg‐1.min‐1, low dose)
Study: 8565164
Drug: OPC-18790 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-18790 (10 micrograms.kg‐1.min‐1, high dose)
Study: 6129869
Drug: Terfenadine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 20 mg 3 times a day
Study: 6129869
Drug: Chlorpheniramine maleate
Normalized name: Chlorpheniramine Maleate
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine maleate 4 mg 3 times a day
Study: 6129869
Drug: Terfenadine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (up to 200 mg 3 times a day)
Study: 31864496
Drug: Stripping twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stripping twice before testicular tissue collection
Study: 17443125
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg nicotine via nasal spray
Study: 18815772
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo via nasal spray
Study: 16035374
Drug: Probiotic multivitamin
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic multivitamin and mineral supplement (verum)
Study: 9661595
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (mid and high doses)
Study: 9661595
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated estrogen (late pubertal dose)
Study: 2655812
Drug: Levamisole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (50 mg, 2 to 5 tablets twice a week for 1 year)
Study: 30895578
Drug: Early diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early diabetes testing (HBA1c, 50 g glucose challenge test, or 100 g oral glucose tolerance test) before 24 weeks
Study: 28344197
Drug: OM3-CA administered
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM3-CA administered after a meal
Study: 28344197
Drug: OM3-CA administered
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM3-CA administered in fasting conditions
Study: 28344197
Drug: OM3-CA administered
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM3-CA administered before a meal
Study: 26447705
Drug: Steroid injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid injections with local anesthetic mixed with deposteroid and 3 rounds of sham PRF
Study: 19808130
Drug: ARF15 BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARF15 BID (15 microg/2 mL twice daily)
Study: 19808130
Drug: ARF30 QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARF30 QD (30 microg/4 mL once daily)
Study: 16394955
Drug: Phosphatidylserine (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylserine (750 mg daily for 10 days)
Study: 15700504
Drug: Concurrent smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent smoking intervention (during alcohol treatment)
Study: 15700504
Drug: Concurrent smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent smoking intervention
Study: 2953527
Drug: Leukotriene D4
Normalized name: Leukotriene D4
DrugBank: Leukotriene D4 (DB11858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukotriene D4 (LTD4) inhalation
Study: 23595153
Drug: Full-dose twice-daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full-dose twice-daily nevirapine
Study: 23595153
Drug: Nevirapine dose-escalation
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine dose-escalation
Study: 17184645
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (100 mg)
Study: 16926261
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist triptorelin 0.1 mg administered on day 6 after ICSI
Study: 2427843
Drug: Celiprolol 200
Normalized name: celiprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol 200 mg once daily
Study: 8405139
Drug: Mode I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mode I: 20 mg hydrocortisone (HC) at 0700 h and 10 mg HC at 1900 h
Study: 8405139
Drug: Mode II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mode II: 30 mg HC at 0700 h and placebo at 1900 h
Study: 8405139
Drug: Mode III:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mode III: Placebo at 0700 h and 30 mg HC at 1900 h
Study: 24812492
Drug: Old 'sticky'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Old 'sticky' tablet
Study: 24812492
Drug: New tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: New tablet formulations (larger API crystal size, 30% more excipients)
Study: 24812492
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg and 50 mg liquid‐filled hard gelatin capsule
Study: 24812492
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg reference tablet
Study: 11851638
Drug: S 18326
Approvals — FDA: no, EMA: no, PMDA: no
Description: S 18326 (0.5 mg h‐1)
Study: 11851638
Drug: S 18326
Approvals — FDA: no, EMA: no, PMDA: no
Description: S 18326 (3 mg h‐1)
Study: 10703776
Drug: Intravenous tPA
Normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tPA (recombinant alteplase)
Study: 1350562
Drug: Terlipressin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (2 mg initially and 1 mg every 4 hr for 24 hr)
Study: 1350562
Drug: Somatostatin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (250 micrograms as a bolus and continuous infusion of 250 micrograms/hr for 24 hr)
Study: 2578707
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg acyclovir four times a day for 12 weeks
Study: 23134891
Drug: Phosphatidylcholine (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylcholine (750 mg)
Study: 18823461
Drug: 660 mg
Normalized name: lactulose 660 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 660 mg of aspirin
Study: 16084069
Drug: Low-dose estrogen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose estrogen replacement therapy (ultralow dose micronized estradiol)
Study: 12190127
Drug: Endoscopy-assisted treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopy-assisted treatment with angulated drills and screwdrivers
Study: 30328294
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (14,000 U weekly for 8 months)
Study: 29121975
Drug: 1 cup
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cup of espresso coffee plus 2 cocoa-based products containing coffee twice per day
Study: 18679151
Drug: Micafungin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin (2 mg/kg)
Study: 18679151
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (3 mg/kg)
Study: 15583955
Drug: Cerebrolysin 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin 50 mL/day for 21 days
Study: 12853587
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (dalteparin) at a dose of 200 IU per kilogram subcutaneously once daily for five to seven days and a coumarin derivative for six months (target INR 2.5)
Study: 12853587
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant (coumarin derivative)
Study: 8967154
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba special extract EGb 761 (3 times 1 film-coated tablet of 40 mg per day)
Study: 1737539
Drug: Two-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose insulin regimen (15% regular, 85% NPH) given before breakfast and dinner
Study: 1737539
Drug: Four-dose insulin
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-dose insulin regimen (regular insulin before meals and NPH at 2200)
Study: 6202098
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg propranolol (Inderal)
Study: 31486833
Drug: EGFR-TKIs plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGFR-TKIs plus metformin (500 mg twice a day)
Study: 24938504
Drug: Network treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Network treatment (intervention group)
Study: 22252217
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg 3 times/week
Study: 20846257
Drug: Oral 600
Normalized name: tolmetin
DrugBank: Tolmetin (DB00500)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 600 microg misoprostol
Study: 20846257
Drug: Sublingual 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual 600 microg misoprostol
Study: 19092248
Drug: CR oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR oxycodone plus pregabalin
Study: 12915604
Drug: High-dose IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IV IL-2 (720,000 U/kg)
Study: 12915604
Drug: Low-dose IV
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IV IL-2 (72,000 U/kg)
Study: 12915604
Drug: Low-dose daily
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose daily subcutaneous IL-2
Study: 10485635
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR (75 or 150 mg/day)
Study: 10485635
Drug: Buspirone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (30 mg/day in 3 divided doses)
Study: 8738759
Drug: R-methadone (tablets)
Normalized name: methadone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-methadone (tablets)
Study: 8738759
Drug: S-methadone (tablets)
Normalized name: methadone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-methadone (tablets)
Study: 2016246
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy for 3 or 6 weeks
Study: 2016246
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy (6 weeks vs. 3 weeks)
Study: 2016246
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy homework compliance
Study: 7127999
Drug: Sustained-release furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release furosemide (FR, 60 mg)
Study: 7127999
Drug: Conventional furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional furosemide tablet (F, 40 mg)
Study: 26729582
Drug: CsA monotherapy
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA monotherapy (n = 98)
Study: 18396071
Drug: Fluoropassiv patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoropassiv patch
Study: 18396071
Drug: Venous patch
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venous patch
Study: 12873261
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 400 mg
Study: 10925929
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (20 g) applied perioperatively and daily for 4 days post-surgery
Study: 8677990
Drug: Mesalamine suspension
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalamine suspension enema (4 g at night)
Study: 8677990
Drug: Oral sulfasalazine
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sulfasalazine (1 g four times a day)
Study: 1986150
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy group - three monthly doses of 500 micrograms of TAA emulsified with CFA
Study: 1986150
Drug: Nonspecific immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonspecific immunotherapy group - three monthly doses of CFA emulsified in saline
Study: 6653642
Drug: Propranolol (P)
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol (P) therapy
Study: 23153388
Drug: Hypnosis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnosis treatment (5 sessions over 2 months)
Study: 17163277
Drug: Average dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average dose of Ziprasidone
Study: 3541946
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate inhaled as a dry-powder, 400 micrograms twice daily
Study: 3541946
Drug: Conventional aerosol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional aerosol, 100 micrograms four times daily
Study: 29683755
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg orally twice daily from day 0 to 5
Study: 22748952
Drug: Third-generation thermal
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-generation thermal uterine balloon therapy (UBT) system with no post-procedure curettage (PPC)
Study: 22748952
Drug: Third-generation thermal
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-generation thermal uterine balloon therapy (UBT) system with post-procedure curettage (PPC)
Study: 8984859
Drug: Bupivacaine 0.0625%
Normalized name: BUPIVACAINE 0.0625%/NS INJ 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.0625% with 2.5 micrograms.ml‐1 fentanyl
Study: 1754638
Drug: Green light
Normalized name: light green SF yellowish
DrugBank: Light green SF yellowish (DB11183)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green light treatment (2 hours each morning for 1 week)
Study: 1754638
Drug: White light
Normalized name: Light White Mineral Oil
DrugBank: Light mineral oil (DB11579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White light treatment (2 hours each morning for 1 week)
Study: 1754638
Drug: Sequence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequence of treatment conditions
Study: 7428802
Drug: Fluoride 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride 3.0 mg as sodium fluoride tablets during acid urine production (induced by NH4Cl)
Study: 7428802
Drug: Fluoride 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride 3.0 mg as sodium fluoride tablets during alkaline urine production (obtained by NaHCO3)
Study: 28586162
Drug: DP10-60 ITF
Approvals — FDA: no, EMA: no, PMDA: no
Description: DP10-60 ITF (8 g/day)
Study: 28586162
Drug: DP2-25 ITF
Approvals — FDA: no, EMA: no, PMDA: no
Description: DP2-25 ITF (8 g/day)
Study: 28586162
Drug: Fructose placebo
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose placebo (8 g/day)
Study: 15036742
Drug: Normothermic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normothermic therapy
Study: 10660238
Drug: PCEA solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA solution of 0.0625% bupivacaine and fentanyl 2 microg/mL (4 mL demand bolus, 15 min lockout) with clonidine 4.5 microg/mL (group BFC)
Study: 10660238
Drug: PCEA solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA solution of 0.0625% bupivacaine and fentanyl 2 microg/mL (4 mL demand bolus, 15 min lockout) without clonidine (group BF)
Study: 2871945
Drug: MPA (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA (500 mg b.i.d. for 6 months)
Study: 26274985
Drug: Parenteral nimodipine
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral nimodipine (1-2 mg/hr) and hydroxyethyl starch (hematocrit 30%-35%) from the day before surgery until the 7th postoperative day
Study: 26274985
Drug: Parenteral nimodipine
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral nimodipine (1-2 mg/hr) and hydroxyethyl starch (hematocrit 30%-35%)
Study: 19023152
Drug: Low-dose abciximab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose abciximab (0.20 mg/kg bolus followed by 12-h infusion)
Study: 19023152
Drug: High-dose abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose abciximab (0.25 mg/kg bolus followed by 12-h infusion)
Study: 19023152
Drug: Placebo (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (bolus and infusion of placebo)
Study: 21046232
Drug: No aromatase
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aromatase inhibitors (no AIs)
Study: 19081397
Drug: 300-mg loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300-mg loading dose of clopidogrel
Study: 16390629
Drug: Micronutrient sprinkles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient sprinkles containing 30 mg Fe/day
Study: 11276275
Drug: Potent pancreatic
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potent pancreatic enzyme supplement (4 capsules with meals, 2 with snacks; lipase 10,000 USP units, protease 37,500 units, amylase 33,200 units)
Study: 7933491
Drug: Ephedrine (EP)
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine (EP) 0.15 mg.kg‐1
Study: 27625146
Drug: Dexamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4 mg, local submucosal injection)
Study: 27625146
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline solution, local submucosal injection)
Study: 20940690
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with carnitine, acetyl carnitine, L-arginine and ginseng
Study: 11305547
Drug: Metronidazole 2
Normalized name: metronidazole 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 2 g suppository
Study: 9369820
Drug: Once-daily gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily gentamicin (4 mg/kg IV every 24 hours) with twice-daily clindamycin (1200 mg IV every 12 hours)
Study: 9369820
Drug: Thrice-daily gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-daily gentamicin (1.33 mg/kg IV every 8 hours) with clindamycin (800 mg IV every 8 hours)
Study: 9369820
Drug: Once-daily gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily gentamicin with twice-daily clindamycin
Study: 9369820
Drug: Thrice-daily gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-daily gentamicin with clindamycin
Study: 1578946
Drug: Monthly myelosuppressive
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly myelosuppressive maintenance for 3 years after initial TAD treatment in the 1981 study.